Syndax Says Pulmonary Fibrosis Drug Trial Misses Primary Endpoint
By Katherine Hamilton
Syndax Pharmaceuticals' trial of a drug to treat idiopathic pulmonary fibrosis didn't meet its primary endpoint.
Based on the results, the New York-based drug company doesn't plan to move forward with future development of axatilimab as a treatment for the lung disease.
The Phase 2 trial of axatilimab didn't meet its target for annualized rate of decline in forced vital capacity, a metric of the total amount of air a patient can forcefully exhale after taking a deep breath.
Shares dropped 13% to $14.45 in after-hours trading Monday.
The safety and tolerability profile was consistent with previous studies. The trial was a 26-week study with 145 patients.
Axatilimab is already approved by the Food and Drug Administration as a treatment after failure of two prior therapies for chronic graft-versus-host disease, a complication that can occur from stem-cell or bone-marrow transplants.
The drug is also being studied in combination with other therapies in patients with newly diagnosed graft-versus-host disease.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
October 12, 2026 16:26 ET (20:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
Christine Benz: Why I Hired a Financial Planner
United States